Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193347 · ClinicalTrials.gov registry record · Phase 1
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
A Phase 1 study of Brain Tumor and Brain Cancer, sponsored by Katy Peters, MD, PhD.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02193347 is a Phase 1 study of Brain Tumor and Brain Cancer that has completed, run by Katy Peters, MD, PhD. The registered enrollment target is 24 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02193347, a Phase 1 study of Brain Tumor and Brain Cancer, has completed, sponsored by Katy Peters, MD, PhD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive testing from the primary tumor (initial diagnosis) will be offered this treatment study in order to test the safety of the PEPIDH1M vaccine in combination with standard chemotherapy (temozolomide).
Conditions Studied
Interventions
- DRUG Temozolomide
- BIOLOGICAL PEPIDH1M vaccine
- BIOLOGICAL Tetanus-Diphtheria Toxoid (Td)
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-01-28 |
| Est. Completion | 2020-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02193347
The ClinicalTrials.gov registry entry for NCT02193347 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (91% lower). The listed sponsor is Katy Peters, MD, PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Brain Tumor appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT02193347 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02193347 about?
NCT02193347 is a clinical study titled "IDH1 Peptide Vaccine for Recurrent Grade II Glioma". Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive testing from the primary tumor (initial diagnosis) will be offered this treatment study in order to test the safety of the PEPIDH1M vaccine in combination with standard chemotherapy (temozolomide).
What is the current status of trial NCT02193347?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-01-28. Estimated completion is 2020-02-03.
What conditions does trial NCT02193347 study?
This clinical trial studies the following conditions: Brain Tumor, Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Cancer of the Brain.
What interventions are being tested in trial NCT02193347?
The interventions under investigation include: Temozolomide (DRUG), PEPIDH1M vaccine (BIOLOGICAL), Tetanus-Diphtheria Toxoid (Td) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02193347?
This trial is sponsored by Katy Peters, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02193347 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.